EGFR and non-small cell lung carcinoma: In the presence of genetic mutations (EGFR, ALK), patients benefit from treatment with selective EGFR inhibitors (e.g., gefitinib and erlotinib) or the ALK inhibitor crizotinib compared to standard chemotherapy for NSCLC tumors [3, 4].